GlaxoSmithKline's corporate venturing unit is now an independent firm with a $500m fund anchored by its former parent.

UK-headquartered pharmaceutical firm GlaxoSmithKline (GSK) spun off its corporate venturing unit, SR One, into an independent venture capital firm yesterday. GSK remains the largest investor in newly rebranded SR One Capital Management’s latest fund, an oversubscribed $500m vehicle also backed by undisclosed asset managers, pension funds, family offices, endowments and foundations. Founded in 1985, SR…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.